Cell Pathways And Squibb Agree Joint Study

Cell Pathways, Inc. and Company plan to cooperate in supporting a clinical trial to study the combination of Aptosyn (exisulind) and TAXOL (paclitaxel) plus Paraplatin (carboplatin) as a first-line treatment for patients with advanced non- small cell lung cancer (NSCLC). This Phase I/II study is designed to evaluate escalating doses of Aptosyn in combination with a standard regimen of TAXOL plus Paraplatin.

The two companies intend to share the costs of this effort and share information.

“Our selective apoptotic anti-neoplastic drugs (SAANDs), including Aptosyn, have demonstrated synergistic anti-cancer effects in preclinical studies when combined with taxanes including TAXOL,” said Rifat Pamukcu, M.D., chief scientific officer of Cell Pathways.

“This new study extends the breadth of our current clinical investigations by using Aptosyn in combination with chemotherapeutic agents commonly used as first-line treatment in patients with NSCLC.

This is an indication where current treatment options are limited, and it is our hope that this drug combination may eventually demonstrate improvement in survival in this high mortality disease.”

Cell Pathways’ lead drug candidate, Aptosyn, is an investigational, oral agent that is designed to selectively trigger programmed cell death, or apoptosis, in precancerous and cancer cells via a mechanism of action different from currently marketed chemotherapeutic agents.

The combination of Bristol-Myers Squibb’s TAXOL and Paraplatin is the most commonly used regimen in community practice for the first-line treatment of NSCLC.

Cell Pathways, Inc., headquartered in Horsham, is a development stage pharmaceutical company focused on the research, development and commercialisation of novel and unique medications to prevent and treat cancer.

Acquire Dragon Pharma On-line

Clomid - Discount Price

Administration: Oral
Main Ingredient: Clomiphene Citrate
Manufacturer: Dragon Pharmaceuticals
Package: 30 x 100 tablets (50 mg/pill)
Price: 30 x $53.00

EQ 300 - Discount Price

Administration: Injection
Basic Substance: Boldenone Undecylenate
Producer: Dragon Pharma
Amount: 30 x 10 mL vial (300 mg/mL)
Price: 30 x $29.00


Synthetic Anabolic Steroidal Agent
Primary Chemical Name: 4-Chlorodehydromethyltestosterone
Manufacturer: Dragon Pharma
Unit: 1 X 100 pills (10 mg/tablet)

Enantat 400

Injectable Anabolic Steroid
Prime Ingredient: Testosterone Enanthate
Manufacturer: Dragon Pharmaceutical
Unit: 1 X 10 ml (400 mg/ml)

Deca 300 - Cheap Price

Administration: Injection
Basal Ingredient: Nandrolone Decanoate
Branded by: Dragon Pharmaceutical
Pack: 20 x 10 mL vial (300 mg/mL)
Price: 20 x $37.00


Synthetic Anabolic Steroidal Agent
Basal Substance: Oxymetholone
Manufacturer: Dragon Pharmaceuticals
Package: 1 X 100 pills (50 mg/pastille)

Enanthat 250

Injectable Steroid for Muscle Growth
Principal Constituent: Testosterone Enanthate
Branded by: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (250 mg/mL)

1-Test Cyp 200

Injectable Steroid for Muscle Growth
Active Constituent: Dihydroboldenone Cypionate
Produced by: Dragon Pharmaceuticals
10 mL Sterile Multi-dose Vial (200 mg/mL)


Prime Constituent: Tamoxifen Citrate
Producer: Dragon Pharmaceuticals
Package: 100 pills (50 mg/pastille)

NPP 150

Basic Chemical Name: Nandrolone Phenylpropionate
Manufacturer: Dragon Pharmaceuticals
Unit: 10 mL vial (150 mg/mL)

EQ 200 / Test E 200

Base Constituent: Boldenone Undecylenate, Testosterone Enanthate
Branded by: Dragon Pharmaceuticals
Amount: 10 mL vial (400 mg/mL)


Basic Ingredient: Tamoxifen Citrate
Manufacturer: Dragon Pharmaceuticals
Unit: 100 tablets (20 mg/pill)